- Home
- SNY vs BAM Comparison
SNY vs BAM Comparison
Compare SNY & BAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNY | BAM |
|---|---|---|
| Founded | 1994 | 2022 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7B | 82.2B |
| IPO Year | 2001 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SNY | BAM |
|---|---|---|
| Price | $48.51 | $51.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | $54.92 | ★ $56.65 |
| AVG Volume (30 Days) | ★ 4.7M | 2.5M |
| Earning Date | 10-30-2026 | 11-06-2026 |
| Dividend Yield | ★ 5.00% | 3.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $4,817,000,000.00 |
| Revenue This Year | $4.70 | $29.33 |
| Revenue Next Year | $5.35 | $16.03 |
| P/E Ratio | ★ $6.14 | $34.43 |
| Revenue Growth | N/A | ★ 21.03 |
| 52 Week Low | $39.07 | $42.20 |
| 52 Week High | $52.67 | $55.98 |
Technical Indicators
Market Signals| Indicator | SNY | BAM |
|---|---|---|
| Relative Strength Index (RSI) | 77.13 | 58.60 |
| Support Level | $45.95 | $51.40 |
| Resistance Level | $48.78 | $53.10 |
| Average True Range (ATR) | 0.87 | 1.63 |
| MACD | 0.53 | 0.32 |
| Stochastic Oscillator | 93.34 | 63.31 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management is one of the world's largest alternative-asset managers, with USD 1.268 trillion in total managed assets, including USD 672.2 billion in fee-earning AUM, at the end of June 2026. The company has three main business segments: real estate/real assets (with USD 686.0 billion in total AUM and USD 292.7 billion in fee-earning AUM), private equity (USD 166.0 billion/USD 53.6 billion), and alternative credit (USD 416.0 billion/USD 325.9 billion). The firm primarily serves institutional investors (90% of AUM) and high-net-worth individuals (10%), and is diversified globally, with 67% of revenue from the Americas, 20% from EMEA, and 13% from Asia-Pacific. Canada-based Brookfield Corporation owns 73% of Brookfield's outstanding Class A shares.